SN1N Stock Chart & Stats
$256.55
$0.00(0.00%)
At close: 4:00 PM EDT
$256.55
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$256.55 - $256.55
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$199.90B
Enterprise Value$12.08K
Total Cash (Recent Filing)$757.91M
Total Debt (Recent Filing)$3.80B
Price to Earnings (P/E)18.2
Beta0.02
Next Earnings
Feb 23, 2027EPS Estimate
10.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.76
Shares Outstanding837,417,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$288.05Price Target Upside12.28% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.25
Revenue Forecast (FY)$1.50B
Bulls Say, Bears Say
Bulls Say
Margin Expansion And EfficiencyHigher trading margins and savings delivered ahead of plan indicate improving operating discipline and a stronger cost structure. If sustained, these efficiencies can protect profitability against moderate revenue pressure and create capacity for investment in products, technology, and commercial execution.
Resilient Cash Generation And LeverageMaintained cash guidance despite a lower revenue outlook demonstrates meaningful financial resilience and supports continued investment, dividends, and buybacks. Leverage remaining within the stated target also preserves balance-sheet flexibility for strategic initiatives and future operating volatility.
Innovation And Sports Medicine MomentumStrong Sports Medicine and ENT growth, supported by multiple launches and regulatory approval, shows a continuing ability to refresh the portfolio and build clinical adoption. Product innovation can broaden the revenue base and improve competitive positioning over the next several quarters.
Bears Say
Lower Revenue Growth OutlookThe guidance reduction signals that near-term demand and commercial execution are weaker than previously expected. Slower top-line growth can limit operating leverage, increase reliance on cost savings to support profit targets, and delay the pace at which the company compounds earnings.
U.S. Orthopaedics Portfolio GapsWeak U.S. knee performance and delayed hip set deployments expose execution and portfolio limitations in a core franchise. Persistent underperformance in orthopaedics could constrain overall growth, reduce leverage from the company’s commercial infrastructure, and require additional investment to regain share.
Reimbursement And Wound-care PressurePayer authorization requirements and CMS reimbursement changes are creating structural friction in Advanced Wound Management rather than merely temporary demand weakness. These pressures may reduce prescription-to-fill conversion, weigh on profitability, and require changes to products and commercial execution.
Smith & Nephew News
SN1N FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest stock price was $256.55 and its highest was $256.55 in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is $199.90B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Feb 23, 2027 which is in 158 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Aug 04, 2026. The company reported $3.66 earnings per share for the quarter, missing the consensus estimate of $8 by -$4.341.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc does not currently pay dividends.
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 10.25.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 837,417,100 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of $3.66 in its last earnings report, missing expectations of $8. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in MX:SN1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$288.05 (12.28% Upside)
$288.05 (12.28% Upside)
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.56%
12-Months-Change
Fundamentals
Return on Equity
2.43%
Trailing 12-Months
Asset Growth
6.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
SN1N Stock 12 Month Forecast
Average Price Target
$288.05
▲(12.28% Upside)